Antiviral Activity of AZD7295 in HCV Carriers

Phase 1CompletedNCT00781976

Arrow Therapeutics31 enrolled

Overview

PK, safety study of AZD7295 in HCV carriers

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

700mg per day maximum

matched placebo

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * HCV carrier Exclusion Criteria: * concurrent medications

Prof Ed Gane

Auckland, New Zealand

Plasma AZD7295 concentrations and pharmacokinetics

Time frame: 5 days

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.